NCT05312697
Source recordAI-normalized
A Phase 2b, Multicenter, Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta
The primary objective of the study is to evaluate bone mineral density (BMD) after 12 months of retreatment with monthly setrusumab in adults with osteogenesis imperfecta (OI).
AI analysis
Indication: Osteogenesis Imperfecta
Modality: monoclonal antibody
Target: Setrusumab
Sponsor: Ultragenyx Pharmaceutical Inc
Source URL: ClinicalTrials.gov
Source updated: Jul 23, 2025
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Setrusumab
View original source fields
Condition raw: Osteogenesis Imperfecta
Condition normalized: Osteogenesis Imperfecta
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Setrusumab
Target normalized: Setrusumab